Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Accretion Pharma. IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2023 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 96  to  101 per share
Profile
Min Investment ₹101
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus --
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Accretion Pharmaceuticals Limited is a rapidly growing pharmaceutical company headquartered in Ahmedabad, Gujarat, India. Established over a decade ago, the company specializes in the manufacturing and marketing of a diverse range of pharmaceutical products, including tablets, capsules, oral liquids, external preparations (such as ointments, creams, gels, lotions, medicated shampoos, mouthwashes, and dusting powders), and oral powders (sachets and dry syrups). Beyond its own product lines, Accretion also offers contract manufacturing services to various marketers, operating primarily on a principle-to-principle basis. The company's manufacturing facility is WHO-cGMP compliant and holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2018 certifications, underscoring its commitment to quality and safety standards Read More

Basic Info

Face Value 10 per share

Price 96  to  101 per share

P/E (x) 11.9

Sales( Cr.) 57

PAT( Cr.) 7

EPS 8.5

Draft Prospectus --

Exchange NSE-SME

Promoter

Company Promoters

Mr. Mayur Popatlal Sojitra Mr. Harshad Nanubhai Rathod Mr. Vivek Ashok Kumar Patel Mr. Hardik Mukundbhai Prajapati.

Pre Issue Share Holding 100%

Post Issue Share Holding 73.48%

Listing Details:

Listing Price: 79

Listing Gain: -27.85%

Current Price: 122.7

Gain On Issue: 122.7 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date May 14, 2025
Closing Date May 16, 2025
Allotment May 19, 2025
Refund May 20, 2025
Delivery of Shares May 20, 2025
Listing Date May 21, 2025

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 1200 121,200
Retail (Max) 1 1200 121,200
S-HNI (Min) 2 2400 242,400
S-HNI (Max) 8 9600 969,600
B-HNI (Min) 9 10800 1,090,800

Objective of the Issue

1. Capital expenditure towards purchase of new equipment/ machineries, etc. 2. Capital expenditure towards upgradation of existing manufacturing facility. 3. Repayment/prepayme nt of certain borrowings availed by the Company. 4. Funding working capital requirements. 5. General Corporate Purpose.

Issue

Category Nos Bid Bid (x)
QIB 1473000 17882220 12.1x
NII 441900 1891332 4.3x
Retail 1031100 10867794 10.5x
EMP 0 0 0x
Total 2946000 22595820 7.7x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Accretion Pharma. Profit & Loss

#(Fig in Cr.) Mar 2024 Mar 2025 TTM
Net Sales 13 57
Other Income 0 0
Total Income 13 57
Total Expenditure 11 45
Operating Profit 3 12
Interest 0 1
Depreciation 0 1
Exceptional Income / Expenses 0 0
Profit Before Tax 2 10
Provision for Tax 1 3
Profit After Tax 1 7
Adjustments 0 0
Profit After Adjustments 1 7
Adjusted Earnings Per Share 2 8.3

Accretion Pharma. Balance Sheet

#(Fig in Cr.) Mar 2024 Mar 2025
Shareholder's Funds 5 15
Minority's Interest 0 0
Borrowings 7 1
Other Non-Current Liabilities 0 0
Total Current Liabilities 15 23
Total Liabilities 27 40
Fixed Assets 5 6
Other Non-Current Assets 0 0
Total Current Assets 22 34
Total Assets 27 40

Accretion Pharma. Cash Flow

#(Fig in Cr.) Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0
Cash Flow from Operating Activities -12 6
Cash Flow from Investing Activities -5 -2
Cash Flow from Financing Activities 17 -4
Net Cash Inflow / Outflow 0 -0
Closing Cash & Cash Equivalent 0 0

Accretion Pharma. Ratios

# Mar 2024 Mar 2025
Earnings Per Share (Rs) 1.96 8.32
CEPS(Rs) 2.26 9.26
DPS(Rs) 0 0
Book NAV/Share(Rs) 7.23 18.71
Core EBITDA Margin(%) 19.19 20.71
EBIT Margin(%) 17.93 19.52
Pre Tax Margin(%) 14.94 17.02
PAT Margin (%) 11.18 11.84
Cash Profit Margin (%) 12.85 13.19
ROA(%) 5.44 20.18
ROE(%) 27.18 65.39
ROCE(%) 12.62 46.33
Receivable days 158.67 55.55
Inventory Days 395.71 111.6
Payable days 256.34 64.77
PER(x) 0 0
Price/Book(x) 0 0
Dividend Yield(%) 0 0
EV/Net Sales(x) 1.3 0.39
EV/Core EBITDA(x) 6.64 1.86
Net Sales Growth(%) 0 329.7
EBIT Growth(%) 0 367.87
PAT Growth(%) 0 355.08
EPS Growth(%) 0 323.34
Debt/Equity(x) 2.45 0.92
Current Ratio(x) 1.47 1.44
Quick Ratio(x) 0.5 0.56
Interest Cover(x) 6 7.79
Total Debt/Mcap(x) 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 338% 0% 0% 0%
Operating Profit CAGR 300% 0% 0% 0%
PAT CAGR 600% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 84% NA% NA% NA%
ROE Average 65% 46% 46% 46%
ROCE Average 46% 29% 29% 29%

Company Contact Information

Accretion Pharmaceuticals Ltd.

29 Xcelon Ind Park 1 B/h, Intas Pharmaceuticals Vasna Chacharvadi, Sanand

IPO Lead Manager(s)

Accretion Pharmaceuticals Ltd.

Jawa Capital Services Private Limited

Registrar Info

Accretion Pharmaceuticals Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!